David J Hamilton
Overview
Explore the profile of David J Hamilton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
483
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sidhu H, Perkins C, Henderson K, Hibl B, Nouer S, Tolley E, et al.
J Am Assoc Lab Anim Sci
. 2024 Feb;
63(3):285-293.
PMID: 38341188
The search for alternatives to live animal sentinels in rodent health monitoring programs is fundamental to the 3Rs (Reduction, Replacement, and Refinement) of animal research. We evaluated the efficacy of...
2.
FitzGerald E, Vagrys D, Opassi G, Klein H, Hamilton D, Talibov V, et al.
SLAS Discov
. 2023 Sep;
29(1):40-51.
PMID: 37714432
Surface plasmon resonance (SPR) biosensor methods are ideally suited for fragment-based lead discovery. However, generally applicable experimental procedures and detailed protocols are lacking, especially for structurally or physico-chemically challenging targets...
3.
Klein H, Hamilton D, de Esch I, Wijtmans M, OBrien P
Drug Discov Today
. 2022 May;
27(9):2484-2496.
PMID: 35636722
In fragment-based drug discovery (FBDD), there is a developing appreciation that 3D fragments could offer opportunities that are not provided by 2D fragments. This review provides an overview of the...
4.
Hamilton D, Beemsterboer M, Carter C, Elsayed J, Huiberts R, Klein H, et al.
ChemMedChem
. 2022 Mar;
17(9):e202200113.
PMID: 35277937
Fragment-based drug discovery (FBDD) has a growing need for unique screening libraries. The cyclobutane moiety was identified as an underrepresented yet attractive three-dimensional (3D) scaffold. Synthetic strategies were developed via...
5.
Hamilton D, Dekker T, Klein H, Janssen G, Wijtmans M, OBrien P, et al.
Drug Discov Today Technol
. 2021 Dec;
38:77-90.
PMID: 34895643
Fragment-based drug discovery (FBDD) has grown into a well-established approach in the pursuit of new therapeutics. Key to the success of FBDD is the low molecular complexity of the initial...
6.
Zhang S, Romero L, Deng S, Wang J, Li Y, Yang L, et al.
ACS Med Chem Lett
. 2021 Apr;
12(4):572-578.
PMID: 33859797
The overactivation of transient receptor potential canonical 3 (TRPC3) is associated with neurodegenerative diseases and hypertension. Pyrazole 3 (Pyr3) is reported as the most selective TRPC3 inhibitor, but it has...
7.
OConnell K, Tigyi G, Livingston R, Johnson D, Hamilton D
J Am Assoc Lab Anim Sci
. 2021 Feb;
60(2):160-167.
PMID: 33629939
Recent studies have evaluated alternatives to the use of live animals in colony health monitoring. Currently, an alternative method that is suitable for all rack types and that has been...
8.
Hamilton D, Abranyi-Balogh P, Keeley A, Petri L, Hrast M, Imre T, et al.
Pharmaceuticals (Basel)
. 2020 Nov;
13(11).
PMID: 33153141
Drug discovery programs against the antibacterial target UDP--acetylglucosamine enolpyruvyl transferase (MurA) have already resulted in covalent inhibitors having small three- and five-membered heterocyclic rings. In the current study, the reactivity...
9.
Komendantov A, Venkadesh S, Rees C, Wheeler D, Hamilton D, Ascoli G
Sci Rep
. 2019 Dec;
9(1):17915.
PMID: 31784578
Systematically organizing the anatomical, molecular, and physiological properties of cortical neurons is important for understanding their computational functions. Hippocampome.org defines 122 neuron types in the rodent hippocampal formation based on...
10.
Sahle F, Kim S, Niloy K, Tahia F, Fili C, Cooper E, et al.
Adv Drug Deliv Rev
. 2019 Nov;
148:290-307.
PMID: 31707052
In recent years, regenerative medicine is gaining momentum and is giving hopes for restoring function of diseased, damaged, and aged tissues and organs and nanotechnology is serving as a catalyst....